Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03374488 · ClinicalTrials.gov registry record · Phase 3
Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
A Phase 3 study of UC (Urothelial Cancer), sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 84
- Enrollment target
- 20
- Study locations
NCT03374488 is a Phase 3 study of UC (Urothelial Cancer) that has completed, run by Incyte Corporation. The registered enrollment target is 84 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT03374488, a Phase 3 study of UC (Urothelial Cancer), has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 84 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab + epacadostat vs pembrolizumab + placebo as a treatment for recurrent or progressive metastatic urothelial carcinoma in patients who have failed a first-line platinum-containing chemotherapy regimen for advanced/metastatic disease.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Placebo
- DRUG Epacadostat
Study Locations (20)
California
- University of California Irvine Medical Center - Orange
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
- UCLA Hematology Oncology Santa Monica - Santa Monica
Pennsylvania
- University of Pennsylvania - Philadelphia
- Thomas Jefferson University Hospital - Philadelphia
- Fox Chase Cancer Center - Philadelphia
Illinois
- University of Chicago - Chicago
- Quincy Medical Group - Quincy
Tennessee
- University of Tennessee Medical Center Knoxville - Knoxville
- Vanderbilt University Medical Center - Nashville
Arizona
- Ironwood Cancer & Research Centers - Chandler
Connecticut
- Smilow Cancer Center at Yale-New Haven - New Haven
Georgia
- Northside Hospital, Inc. - GCS/Annex - Atlanta
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2017-12-22 |
| Est. Completion | 2020-07-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03374488
The ClinicalTrials.gov registry entry for NCT03374488 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with UC (Urothelial Cancer) appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03374488 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Pennsylvania, Illinois.
Frequently Asked Questions
What is clinical trial NCT03374488 about?
NCT03374488 is a clinical study titled "Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma". The purpose of this study was to evaluate the efficacy and safety of pembrolizumab + epacadostat vs pembrolizumab + placebo as a treatment for recurrent or progressive metastatic urothelial carcinoma in patients who have failed a first-line platinum-containing chemotherapy regimen for advanced/metas...
What is the current status of trial NCT03374488?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 84 participants. The study started on 2017-12-22. Estimated completion is 2020-07-23.
What conditions does trial NCT03374488 study?
This clinical trial studies the following conditions: UC (Urothelial Cancer).
What interventions are being tested in trial NCT03374488?
The interventions under investigation include: Pembrolizumab (DRUG), Placebo (DRUG), Epacadostat (DRUG).
Who is sponsoring clinical trial NCT03374488?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03374488 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for UC (Urothelial Cancer)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.